Therapeutic potential of panduratin A, LKB1-dependent AMP-activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesity

Diabetes, Obesity and Metabolism

Volumn 13, Issue 7, 2011, Pages 584-593

  Kim, D ^a   Lee, M S ^a   Jo, K ^a   Lee, K E ^a   Hwang, J K ^a  

^a Yonsei University   (South Korea)

Author keywords

AMP activated protein kinase; Fatty liver; LKB1; Obesity; Panduratin A; PPAR

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIOBESITY AGENT; BIOLOGICAL MARKER; CYTOCHROME C; CYTOCHROME C OXIDASE; GALACTOSIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA 2 SUBUNIT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MITOCHONDRIAL DNA; MYOGLOBIN; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN ALPHA; PANDURATIN A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE LKB1; SMALL INTERFERING RNA; SUCCINATE DEHYDROGENASE; TRIACYLGLYCEROL; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOESENBERGIA PANDURATA; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; MALE; MEDICINAL PLANT; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCLE METABOLISM; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RHIZOME; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 79956320223     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01379.x     Document Type: Article

References (19)

1. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004; 11: 3-8.
2. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
3. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783.
4. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-341.
5. Witczak CA, Sharoff CG, Goodyear LJ. AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. Cell Mol Life Sci 2008; 65: 3737-3755.
6. Lee YS, Kim WS, Kim KH et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006; 55: 2256-2264.
7. Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007; 3: 33-39.
8. Bronner M, Hertz R, Bar-Tana J. Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor alpha by AMP-activated protein kinase. Biochem J 2004; 384: 295-305.
9. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol 2007; 27: 4317-4327.
10. Narkar VA, Downes M, Yu RT et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134: 405-415.
11. Lagouge M, Argmann C, Gerhart-Hines Z et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122.
12. Hwang JH, Kim DW, Jo EJ et al. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes 2009; 58: 965-974.
13. Shindo K, Kato M, Kinoshita A, Kobayashi A, Koike Y. Analysis of antioxidant activities contained in the Boesenbergia pandurata Schult. Rhizome. Biosci Biotechnol Biochem 2006; 70: 2281-2284.
14. Yun JM, Kwon H, Hwang JK. In vitro anti-inflammatory activity of panduratin A isolated from Kaempferia pandurata in RAW264.7 cells. Planta Med 2003; 69: 1102-1108.
15. Sohn JH, Han KL, Lee SH, Hwang JK. Protective effects of panduratin A against oxidative damage of tert-butylhydroperoxide in human HepG2 cells. Biol Pharm Bull 2005; 28: 1083-1086.
16. Han KL, Choi JS, Lee JY et al. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 2008; 57: 737-745.
17. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008; 117: 952-962.
18. Wang YX, Zhang CL, Yu RT et al. Regulation of muscle fiber type and running endurance by PPAR delta. PLoS Biol 2004; 2: e294.
19. Yki-Järvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med 2002; 95(Suppl. 42): 39-45.